Does dual antidepressant therapy as initial treatment hasten and increase remission from depression?

Journal of Psychiatric Practice

Volumn 15, Issue 5, 2009, Pages 337-345

  Stewart, Jonathan W ^a,b   McGrath, Patrick J ^a   Deliyannides, Rodeborah A ^a   Quitkin, Frederic M ^b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b NONE

Author keywords

Bupropion; Depression; Dual therapy; Early remission; Escitalopram; Remission

Indexed keywords

AMFEBUTAMONE; ESCITALOPRAM;

ADULT; ANXIETY; ARTICLE; BECK DEPRESSION INVENTORY; BLOATING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DECREASED APPETITE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAPHORESIS; DIARRHEA; DIZZINESS; DREAMING; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; DYSTHYMIA; ERECTILE DYSFUNCTION; FEMALE; GASTROINTESTINAL SYMPTOM; HAMILTON SCALE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MUSCLE TONE; MUSCLE TWITCH; NAUSEA; OPEN STUDY; ORGASM DISORDER; PARESTHESIA; REMISSION; RESTLESS LEGS SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; TASTE DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; URINARY HESITANCY; URTICARIA; XEROSTOMIA; YAWNING;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; CITALOPRAM; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; DYSTHYMIC DISORDER; FEMALE; HUMANS; MALE; OBSERVER VARIATION; PILOT PROJECTS; REMISSION INDUCTION;

EID: 70349751881     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000361276.88339.44     Document Type: Article

References (59)

1. Piñeyro G, Blier P. Autoregulation of serotonin neurons: Role in antidepressant drug action. Pharmacol Rev 1999; 51:533-591 (Pubitemid 29420214)
2. El Mansari M, Sanchez C, Chouvet G, et al. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: An in vivo electrophysiological study in rat brain. Neuropsychopharmacology 2005;30:1269-1277 (Pubitemid 40848081)
3. Baron BM, Ogden AM, Siegel BW, et al. Rapid down regulation of beta-adrenoceptors by co-administration of desipramine and fluoxetine. Eur J Pharmacology 1988; 154:125-134
4. Duman RS. Synaptic plasticity and mood disorders. Mol Psychiatry 2002;7(suppl 1):S29-S34.
5. Hashimoto K, Shimizu E, Iyo M. Critical role of brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. Brain Res Brain Res Rev 2004;45:104-114
6. Malberg JE, Eisch AJ, Nestler EJ, et al.. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neuroscience 2000;20:9104-9110 (Pubitemid 32042912)
7. Santarelli L, Saxe M, Gross C, et al.. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301:805-809
8. Simpson GM, Lee JH, Cuculic Z, et al. Two dosages of imipramine in hospitalized endogenous and neurotic depressives. Arch Gen Psychiatry 1976;33:1093-1102.
9. Watt DC, Crammer JL, Elkes A. Metabolism, anticholinergic effects and therapeutic effects and outcome of desipramine in depressive illness. Psychosom Med 1972;2: 397-405.
10. Bech P, Kajdasz DK, Porsdal V. Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. Psychopharmacology 2006;188:273-280 (Pubitemid 44387455)
11. Schweizer E, Rickels K, Amsterdam JD, et al. What constitutes an adequate antidepressant trial for fluoxetine? J Clin Psychiatry 1990;51:8-11.
12. Kornstein SG, Dunner DL, Meyers AL, et al. A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy. J Clin Psychiatry 2008;69:1383-1392
13. Depression Guideline Panel. Depression in primary care: Volume 1. Detection and diagnosis. Clinical practice guideline, Number 5. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 93-0550, 1993.
14. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000;157(4 Suppl):1-45. (Pubitemid 30193855)
15. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin re-uptake inhibitors. Br J Psychiatry 2001;178:234-241 (Pubitemid 32183606)
16. Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A metaanalysis. Br J Psychiatry 2002;180:396-404. (Pubitemid 34499333)
17. Trivedi M, Rush J,Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurementbased care in STAR*D: Implications for clinical practice. Am J Psychiatry 2006;163:28-40. (Pubitemid 43050100)
18. Quitkin FM, McGrath PJ, Stewart JW, et al. Remission rates with 3 consecutive antidepressant trials: Effectiveness for depressed outpatients. J Clin Psychiatry 2005;66: 670-676
19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition. Washington, DC: American Psychiatric Association; 1994.
20. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, Version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute; 1996.
21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-60.
22. Guy W, ed. ECDEU assessment manual for psychopharmacology: Publication ADM 76-338. Washington, DC: US Department of Health, Education, and Welfare; 1976: 218-22..
23. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4: 561-571
24. Stassen HH, Angst J, Delini-Stula A. Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses. Pharmacopsychiatry 1996;29:87-96. (Pubitemid 26150434)
25. Stassen HH, Angst A. Delayed onset of action of antidepressants: Fact or fiction? CNS Drugs 1998;9:177-184
26. Nierenberg AA, Greist JH, Mallinckrodt CH, et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: Onset of antidepressant action, a non-inferiority study. Curr Med Res Opin 2007;23:401-416 (Pubitemid 46333388)
27. Montgomery SA, Baldwin DS, Blier P, et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharm 2007;22:323-329 (Pubitemid 47530836)
28. Yevtushenko VY, Belous AI, Yevtushenko YG, et al. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: A 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Clinical Therapeutics 2007;29: 2319-2332
29. Quitkin FM, Taylor BP, Kremer C. Does mirtazapine have a more rapid onset than SSRIs? J Clin Psychiatry 2001;62: 358-361
30. Ghanbari R, El Mansari M, Blier P. Electrophysiological effects of the co-administration of escitalopram and bupropion on rat serotonin and norepinephrine neurons. J Psychopharmacol. 2008 Nov 21 [Epub ahead of print].
31. Li SX-M, Perry KW, Wong DT. Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology 2002;42:181-190
32. Papakostas GI, Montgomery SA, Thase ME, et al. Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: A pooled survival analysis of 7 double-blind, randomized clinical trials. J Clin Psychiatry 2007;68:1907-1912
33. Leuchter AF, Lesser IM, Trivedi MH, et al. An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. J Psychiatric Practice 2008;14:271-280
34. Bodkin JA, Lasser RA,Wines JD Jr, et al. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997;58:137-145
35. DeBattista C, Solvason HB, Poirier J, et al. A prospective trial of bupropion SR augmentation of partial and nonresponders to serotonergic antidepressants. J Clin Psychopharmacology 2003;23:27-30. (Pubitemid 36164422)
36. Kennedy SH, McCann SM, Masellis M, et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: A preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 2002; 63:181-186 (Pubitemid 34407075)
37. Marshall RD, Liebowitz MR. Paroxetine/bupropion combination treatment for refractory depression [letter]. J Clin Psychiatry 1996;16:80-81 (Pubitemid 26060755)
38. Spier SA. Use of bupropion with SSRIs and venlafaxine. Depression & Anxiety 1998;7:73-75
39. Silverstone PH, Entsuah R, Hackett D. Two items on the Hamilton Depression rating scale are effective predictors of remission: Comparison of selective serotonin reuptake inhibitors with the combined serotonin/ norepinephrine reuptake inhibitor, venlafaxine. Int Clin Psychopharmacology 2002;17:273-280 (Pubitemid 35283714)
40. Entsuah R, Derivan A, Kikta D. Early onset of antidepressant action of venlafaxine: Pattern analysis in intent-totreat patients. Clin Therapeutics 1998;20:517-526 (Pubitemid 28343504)
41. Shelton C, Entsuah R, Padmanabhan SK, et al. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. Int Clin Psychopharmacology 2005;20:233-238 (Pubitemid 40896379)
42. Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: A pooled analysis of patients with depression. Biol Psychiatry 2002;52:1166-1174 (Pubitemid 35477672)
43. Entsuah R, Gorman JM. Global benefit-risk assessment of antidepressants: Venlafaxine XR and fluoxetine. J Psychiatr Res 2002;36:111-118 (Pubitemid 34218951)
44. Bielski RJ, Ventura D, Chang C-C. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004;65:1190-1196
45. Khan A, Bose A, Alexopoulos GS, et al. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Investig 2007;27:481-492 (Pubitemid 46919700)
46. Nierenberg AA, Greist JH, Mallinckrodt CH, et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: Onset of antidepressant action, a non-inferiority study. Curr Med Res Opin 2007;23:401-416 (Pubitemid 46333388)
47. Lam RW, Andersen HF,Wade AG. Escitalopram and duloxetine in the treatment of major depressive disorder: A pooled analysis of two trials. Int Clin Psychopharm 2008; 23:181-187
48. van Moffaert M, de Wilde J, Vereecken A, et al. Mirtazapine is more effective than trazodone: A double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharm 1995;10:3-9.
49. Nelson JC, Mazure CM, Bowers MB Jr, et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991;48:303-307
50. Nelson JC, Mazure CM, Jatlow PI, et al. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: A double-blind, randomized study. Biol Psychiatry 2004;55:296-300.
51. Ballesteros J, Callado LF. Effectiveness of pindolol plus serotonin uptake inhibitors in depression: A meta-analysis of early and late outcomes from randomised controlled trials. J Affect Disord 2004;79:137-147 (Pubitemid 38340537)
52. Segrave R, Nathan P. Pindolol augmentation of selective serotonin reuptake inhibitors: Accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression. Hum Psychopharmacol 2005;20:163-174 (Pubitemid 40561850)
53. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: Fluoxetine, paroxetine, sertraline and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997;23:176-194 (Pubitemid 27514710)
54. Clayton AH, Pradko JF, Croft HA. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63:357-366
55. Labbate LA, Pollack MH. Treatment of fluoxetine-induced sexual dysfunction with bupropion: A case report. Ann Clin Psychiatry 1994;6:13-15
56. Ashton AD, Rosen RC. Bupropion as an antidote for serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 1998;59:112-115 (Pubitemid 28150856)
57. DeBattista C, Solvason B, Poirier J, et al. A placebo-controlled randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. J Clin Psychiatry 2005;66: 844-848 (Pubitemid 41032825)
58. Clayton AH, Warnock JK, Kornstein SG, et al. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 2004;65:62-67
59. Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: Variable, substantial, and growing. JAMA 2002;287:1840-1847 (Pubitemid 34303629)